Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

FOUND: Biogen earnings preview what to expect b9751d87 8d72 4be3 8cc1 1e842c33ca38 - What They Never Told You

With a market cap of $26 billion, Biogen Inc. (BIIB) is a global biotechnology company that discovers, develops, and delivers therapies for neurological, autoimmune, and rare diseases across the United States, Europe, and other international markets. Its portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and various cancers, alongside collaborations with leading pharmaceutical and research organizations.

The Cambridge, Massachusetts-based company is set to unveil its fiscal Q1 2026 results before the market opens on Wednesday, Apr. 29. Ahead of this event, analysts expect BIIB to report an adjusted EPS of $3, down marginally from $3.02 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.